Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
November 03 2021 - 2:30AM
Business Wire
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced its participation at upcoming investor and scientific
conferences in November 2021.
- AASLD The Liver Meeting (virtual) Date: November 12-15,
2021 Poxel will present a poster entitled: “FIB-4 score as a
predictive factor of advanced liver fibrosis should be adapted
according to type 2 diabetes status: screening data from DESTINY-1
(PXL065) phase 2 study.”
- Jefferies London Healthcare Conference (in-person and
virtual) Date: November 16-19, 2021 London, UK Poxel management
team members will be available for one-to-one in-person meetings on
November 16-17, 2021, and for virtual meetings on November 18,
2021. Thomas Kuhn, CEO, will present on November 16, 2021 at 1:00pm
GMT / 8:00 am ET.
- 5th Annual NASH Summit (virtual) Date: November 29 -
December 2, 2021 David Moller, Executive Vice President, Chief
Scientific Officer (CSO), will participate and present at this
conference.
As part of increasing its focus on rare diseases and on X-linked
adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease
with no approved therapies, Poxel will also be represented at the
following events:
- ALD Connect Annual Meeting (virtual) Date: November 12-13,
2021 David Moller, Executive Vice President, Chief Scientific
Officer (CSO), will participate and present at this conference
Poxel programs targeting adrenoleukodystrophy (ALD).
- Alex The Leukodystrophy Charity Digital Community
Weekend 2021 (virtual) Date: November 20-21, 2021 David Moller,
Executive Vice President, Chief Scientific Officer (CSO), will
present Poxel programs targeting adrenoleukodystrophy (ALD).
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing
innovative treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare disorders. Poxel has clinical and earlier-stage programs from
its adenosine monophosphate-activated protein kinase (AMPK)
activator and deuterated TZD platforms targeting chronic and rare
metabolic diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator,
has successfully completed a Phase 2a proof-of-concept trial for
the treatment of NASH, which met its objectives. For the rare
inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that
targets mitochondrial dysfunction, has been approved and launched
for the treatment of type 2 diabetes in Japan. Poxel expects to
receive sales-based payments and royalties from Sumitomo Dainippon
Pharma. Poxel has a strategic partnership with Sumitomo Dainippon
Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine
other Southeast Asian countries. The Company intends to generate
further growth through strategic partnerships and pipeline
development. Listed on Euronext Paris, Poxel is headquartered in
Lyon, France, and has subsidiaries in Boston, MA, and Tokyo,
Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102006426/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78
Aurélie Bozza Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
Investor relations / Media NewCap Emmanuel Huynh or
Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Poxel (EU:POXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024